Santibáñez MÁ, Colín LEO, Durán BE, Sánchez SP, Pashkova O

Language: Spanish
References: 10
Page: 307-313
PDF size: 338.71 Kb.

ABSTRACT

Background: Nowadays various assisted reproduction ovarian stimulation schemes are used for different clinical outcomes is interesting to compare.
Objective: Compare two ovarian stimulation protocols: recombinant FSH + LH versus recombinant FSH + Menotropins.
Material and methods: Observational, retrospective study, 38 cycles were analyzed, made from 2010 until 2013, assigned to two groups (n=19 each), group 1 received FSHr + LHr, group 2 received FSHr + menotropins. Study variables were: days of ovarian stimulation, total gonadotropin dose, retrieved oocytes, fertilization rate, pregnancy rate and number of vitrified embryos.
Results: Fewer stimulation days (8.5 ± 1.5 vs 9 ± 1.1) were found in group 1 (recombinant gonadotropins). Group 2 (FSHr + Menotropins), had a greater total dose of gonadotropins (1930.2 ± 346.2 vs 2000 ± 418.8) and more retrieved oocytes (8.15 ± 3.9 vs 8.57 ± 4). Group 1 patients had higher pregnancy and fertilization rates (56.2 vs 36.8%, and 75.4 vs 69.3%) respectively, no statistical significance was found.
Conclusion: This study found higher pregnancy and fertilization rates in patients treated with recombinant gonadotropins (FSH + LH) for ovarian stimulation.

REFERENCES

1. Vegetti W, Alagna F. FSH and folliculogenesis: from physiology to ovarian stimulation. Reproductive Biomedicine Online 2006;12:684-694

2. Le Cotonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertility and Sterility 1998;69:16S-23S.

3. Levi-Setti P, Cavagna M, Bullti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: Comparison of r-FSH alone and in combinantion with r-LH. European Journal of Obstetrics and Gynaecology and Reproductive Biology 2006;126:212-216.

4. Baruffi R, Petersen CG, Felipe V, Martins AMC, Cornicelli J, Cavagna M, et al. Recombinant LH supplementation to recombinan FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reproductive BioMedicine Online 2006;14:14-25.

5. Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertility and Sterility 2010; 96: 2467-2469.

6. Marrs R, Maeldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undegoing assisted reproduction treatment. Reproductive Biomedicine Online 2003;8:175-182.

7. Hill M, Levens E, Levy G, Ryan M, Csokmay J, DeCherney A, Whitcomb W. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertility and Sterility 2012;97:1108-114.

8. Humaidan P, Bungum M, Bungum L, Andersen CY. Effects of recombinant LH suppementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedicine Online 2004;8:635-643.

9. Levi-Setti P, Cavagna M, Baggiani A, Zannoni E, Colombo G, Liprandi V. FSH and LH together in ovarian stimulation. European Journal of Obstetrics and Gynecology and Reproductive Biology 2004;115S:S34-S39.

10. Nargund G, Fauser BCJM, Macklon NS, Ombelet W, Nygren K, Frydman R. The ISSSMAAR proposal on terminology for ovarian stimulation for IVF. Human Reproduction 2007;22:2801-2804.